Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30

Blood

Volumn 110, Issue 13, 2007, Pages 4370-4372

  Oflazoglu, Ezogelin ^a   Stone, Ivan J ^a   Gordon, Kristine A ^a   Grewal, Iqbal S ^a   Van Rooijen, Nico ^b   Law, Che Leung ^a   Gerber, Hans Peter ^a  

^a SEATTLE GENETICS INC   (United States)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD30 ANTIGEN; MONOCLONAL ANTIBODY; SGN 30; MONOCLONAL ANTIBODY SGN-30; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DNA FRAGMENTATION; EFFECTOR CELL; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; MACROPHAGE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; SCID MOUSE; ANIMAL; CANCER TRANSPLANTATION; DRUG EFFECT; IMMUNOLOGY; MOUSE MUTANT; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD30; CELL LINE, TUMOR; HODGKIN DISEASE; HUMANS; MACROPHAGES; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; PHAGOCYTOSIS; TRANSPLANTATION, HETEROLOGOUS;

EID: 39649122877     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-06-097014     Document Type: Article

References (18)

1. Kaudewitz P, Stein H, Burg G, Mason DY, Braun-Falco O. Atypical cells in lymphomatoid papulosis express the Hodgkin cell-associated antigen Ki-1. J Invest Dermatol. 1986;86:350-354.
2. Chiarle R, Podda A, Prolla G, Gong J, Thorbecke GJ, Inghirami G. CD30 in normal and neoplastic cells. Clin Immunol. 1999;90:157-164.
3. Anagnostopoulos I, Hansmann ML, Franssila K, et al. European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood. 2000;96:1889-1899.
4. Wahl AF, Klussman K, Thompson JD, et al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res. 2002;62:3736-3742.
5. Cerveny CG, Law CL, McCormick RS, et al. Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics. Leukemia. 2005;19:1648-1655.
6. Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods. 1994;174:83-93.
7. McEarchern JA, Oflazoglu E, Francisco L, et al. Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. Blood. 2007;109:1185-1192.
8. van Rooijen N, Sanders A. Elimination, blocking, and activation of macrophages: three of a kind. J Leukoc Biol. 1997;62:702-709.
9. Uchida J, Hamaguchi Y, Oliver JA, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med. 2004;199:1659-1669.
10. Gong Q, Ou Q, Ye S, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol. 2005;174:817-826.
11. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006;66:605-612.
12. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99:754-758.
13. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21:3940-3947.
14. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood. 1997;90:1109-1114.
15. Wu J, Edberg JC, Redecha PB, et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest. 1997;100:1059-1070.
16. Shields RL, Namenuk AK, Hong K, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem. 2001;276:6591-6604.
17. Farag SS, Flinn IW, Modali R, Lehman TA, Young D, Byrd JC. Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood. 2004;103:1472-1474.
18. Lin TS, Flinn IW, Lucas MS, et al. Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia. Leukemia. 2005;19:1207-1210.